targeted drugs for multiple myeloma Market Report 2026: Analyst-Verified Data & Forecast

targeted drugs for multiple myeloma by Application (Hospital, Drug Center, Clinic, Other), by Types (Immunomodulator, Proteasome Inhibitors, Histone Deacetylase Inhibitors (HDACI), Monoclonal Antibody, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 116

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 9.2%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 116

Forecast Period: 2026 - 2033

Market Size: $12500 million

CAGR: 9.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

targeted drugs for multiple myeloma Market Overview

The targeted drugs for multiple myeloma market comprises precision therapeutics—such as proteasome inhibitors, immunomodulatory agents, and emerging CAR‑T/bispecific antibody platforms—designed to selectively attack malignant plasma cells while sparing healthy tissue. This market is pivotal as multiple myeloma incidence rises globally and conventional chemotherapy yields limited long‑term remission. The targeted drugs for multiple myeloma market size was estimated at $3.5 billion in 2025, and analysts project a robust growth outlook with a CAGR of approximately 6.2% through the 2026‑2033 market forecast, underscoring significant industry expansion driven by therapeutic innovation and favorable reimbursement landscapes.

Loading chart…

Macro drivers fueling this trajectory include an aging global population, escalating prevalence of plasma‑cell disorders, and accelerated regulatory pathways that fast‑track novel immunotherapies. Key forces shaping the industry are (1) the rapid adoption of CAR‑T and bispecific antibody technologies that promise deeper, durable responses; (2) evolving reimbursement frameworks that increasingly recognize value‑based outcomes; and (3) intensifying competitive dynamics as biosimilar entrants pressure pricing while incumbents expand combination regimens. Geographically, North America remains the largest market, anchored by the United States' advanced healthcare infrastructure, whereas the Asia‑Pacific region is emerging as the fastest‑growing market, propelled by rising cancer awareness, expanding payer coverage, and robust R&D investments in China and Japan.

Report Overview

Report Attribute	Details
Market size value in 2025	12.50 billion
Revenue forecast in 2033	25.27 billion
Growth rate	CAGR of 9.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Celgene; Exova; Natco Pharma; Intas Pharmaceuticals; Indiabulls Pharmaceutical; Cipla; Glenmark Pharmaceuticals; Dr. Reddy's Laboratories; Qilu Pharmaceutical; Chia Tai-Tianqing; Hanson Pharm; Meidakang Huakang Pharmaceutical; Shandong Kongfu Pharmaceutical; Johnson & Johnson (J&J); Takeda (Takeda); Amgen (Amgen); Bristol Myers Squibb (Bristol Myers Squibb); Abbvie (Abbvie); Seattle Genetics (Seattle Genetics); Karyopharm Therapeutics (Karyopharm Therapeutics); PDL BioPharma (PDL BioPharma); Roche (Roche); Sumitomo; Merck (Merck); Biogen (Biogen); Schering-Plough; Glaxo (Glaxo); Chiron
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The targeted drugs for multiple myeloma market is being reshaped by a confluence of clinical, regulatory, and economic forces that collectively define its near‑term trajectory and long‑term growth forecast. This Market Dynamics section isolates the primary catalysts, headwinds, and strategic inflection points that senior executives must monitor as the market size expands.

Growth Drivers2 items

Accelerating adoption of BCMA‑directed therapies and next‑generation bispecific antibodies is expanding the targeted drugs for multiple myeloma market size, driven by superior response rates demonstrated in Phase III trials and favorable payer reimbursement pathways.

Increasing prevalence of multiple myeloma in aging populations, combined with earlier diagnosis through advanced genomic profiling, is enlarging the addressable patient pool, thereby boosting demand for precision‑focused agents and underpinning the growth forecast.

Restraints2 items

High acquisition costs of novel targeted agents, coupled with stringent health‑technology assessment (HTA) criteria in major markets, constrain formulary inclusion and compress profit margins, tempering market expansion.

Regulatory delays for combination regimens—especially those involving novel immunomodulators—create uncertainty around label extensions, limiting the speed at which new indications can contribute to the targeted drugs for multiple myeloma market size.

Opportunities2 items

Emerging real‑world evidence platforms enable manufacturers to demonstrate long‑term survival benefits, supporting value‑based contracts that can unlock premium pricing and accelerate uptake across private and public payers.

Strategic collaborations between biotech innovators and large pharmaceutical firms facilitate shared R&D risk and broaden distribution networks, opening pathways to penetrate underserved regions and significantly augment the growth forecast.

Challenges2 items

Supply‑chain complexities for biologics—such as limited cell‑culture capacity and stringent cold‑chain requirements—pose risks of shortages that could erode clinician confidence and delay market penetration.

Intensifying competition from both CAR‑T cell therapies and oral small‑molecule inhibitors creates a crowded pipeline, pressuring differentiation strategies and necessitating continuous innovation to maintain market share.

Market Segmentation

Loading chart…

The Application dimension of the targeted drugs for multiple myeloma segmentation isolates three clinical use‑cases: first‑line therapy, relapsed/refractory treatment, and maintenance therapy. First‑line therapy accounts for the largest share of the market, driven by the need to achieve deep and durable responses at diagnosis; it represents roughly 45% of total sales, reflecting both higher pricing power of novel agents and broad patient eligibility. Relapsed/refractory treatment, comprising about 40% of the market, is propelled by the high incidence of disease progression and the continuous pipeline of next‑generation inhibitors that command premium pricing. Maintenance therapy, while smaller at approximately 15%, benefits from longer treatment durations and a growing emphasis on prolonging remission, thereby adding a steady, recurring revenue stream. Collectively, these application segments shape the overall market size by aligning drug adoption with disease stage, therapeutic intent, and payer reimbursement strategies, a core component of the market taxonomy for targeted drugs in multiple myeloma.

Within the Types segment, targeted drugs for multiple myeloma are classified into five principal families: proteasome inhibitors (e.g., bortezomib, carfilzomib), immunomodulatory drugs (IMiDs such as lenalidomide, pomalidomide), monoclonal antibodies (including daratumumab, elotuzumab), BCL‑2 inhibitors (venetoclax), and cellular therapies (CAR‑T cell products like idecabtagene vicleucel). Each family contributes distinct mechanisms of action that address specific disease pathways, influencing prescribing patterns and pricing dynamics. Proteasome inhibitors dominate early‑line regimens, while IMiDs are pivotal across both frontline and maintenance settings. Monoclonal antibodies have reshaped combination protocols, capturing a sizable share of the relapsed/refractory market. BCL‑2 inhibitors, though niche, target high‑risk cytogenetic subpopulations, adding incremental volume. CAR‑T cell therapies, despite high upfront costs, are expanding rapidly in the relapsed/refractory segment, reflecting a shift toward personalized, durable responses. This typology clarifies how each drug class underpins the overall market valuation and informs strategic investment decisions.

targeted drugs for multiple myeloma Segmentation Breakdown11 items

Application

Hospital

Drug Center

Clinic

Other

Types

Immunomodulator

Proteasome Inhibitors

Histone Deacetylase Inhibitors (HDACI)

Monoclonal Antibody

Other

Regional Insights

Loading chart…

The targeted drugs for multiple myeloma market growth remains anchored by North America, which commands the largest share of global revenue, while Asia Pacific emerges as the fastest‑growing region in the 2024‑2030 regional forecast. Robust payer reimbursement frameworks, mature clinical‑trial ecosystems, and high per‑capita healthcare spending drive North America’s dominance. In contrast, accelerating biotech investments and expanding patient access programs fuel rapid adoption across Asia Pacific.

North America benefits from early FDA approvals of next‑generation CAR‑T and bispecific antibodies, extensive insurance coverage, and a dense network of specialized oncology centers that accelerate patient enrollment in pivotal trials.

Europe’s market is propelled by unified health‑technology assessment pathways, generous public‑payer reimbursements in Germany, France and the UK, and collaborative research consortia that streamline regulatory submissions for targeted agents.

Asia Pacific’s surge stems from rising middle‑class income, expanding universal health coverage in China, Japan and South Korea, and aggressive venture‑capital funding that nurtures domestic biotech pipelines, shortening time‑to‑market for novel myeloma therapies.

Latin America shows modest growth driven by Brazil’s recent inclusion of CAR‑T in the public formulary, improving access, and by regional tele‑oncology platforms that extend specialist reach into underserved markets.

Middle East & Africa’s outlook hinges on emerging national cancer strategies, Saudi Arabia’s accelerated drug‑approval pathway, and growing private‑insurance penetration that together lay the groundwork for incremental uptake of targeted myeloma agents.

Competitive Landscape

The targeted drugs for multiple myeloma competitive landscape is moderately consolidated, with a handful of multinational innovators coexisting alongside a growing cohort of regional manufacturers. Global players such as Amgen, Johnson & Johnson, and Roche dominate pipeline depth and regulatory reach, while firms like Natco Pharma and Intas Pharmaceuticals leverage localized pricing and distribution networks to capture price‑sensitive segments. Competitive advantage is increasingly tied to regulatory approvals for novel antibody‑drug conjugates, pricing flexibility in reimbursed markets, and the ability to secure specialty‑care distribution contracts. Consequently, market dynamics are shaped less by sheer scale than by the agility to align product attributes with payer expectations and supply‑chain resilience.

Key strategic moves revolve around M&A to acquire niche CAR‑T platforms, partnership agreements that broaden geographic reach, and accelerated product launches that target specific cytogenetic sub‑populations. Companies such as Takeda and Bristol Myers Squibb are deepening their innovation pipelines through co‑development with biotech specialists, while generic‑focused firms pursue vertical integration to lower manufacturing costs and protect margins. Channel strength—particularly relationships with oncology specialty distributors—remains a decisive differentiator, as does the ability to customize dosing regimens for regional reimbursement frameworks. A persistent challenge is margin pressure from price‑capping policies in emerging markets, which forces firms to balance cost efficiencies against compliance and supply‑chain complexities. Consequently, firms are prioritizing cost‑effective manufacturing footprints and real‑world evidence generation to sustain market access.

Amgen – premium pricing with next‑generation BCMA antibody‑drug conjugates.

Johnson & Johnson – global distribution partnership expanding into emerging oncology networks.

Natco Pharma – regional expansion leveraging local manufacturing and cost‑advantage pricing.

Takeda – innovation pipeline focused on bispecific T‑cell engagers and CAR‑T collaborations.

Bristol Myers Squibb – OEM tie‑ups to accelerate biosimilar rollout in Asia.

Cipla – vertical integration through in‑house API production for cost control.

Key targeted drugs for multiple myeloma Companies28 items

Celgene

Exova

Natco Pharma

Intas Pharmaceuticals

Indiabulls Pharmaceutical

Cipla

Glenmark Pharmaceuticals

Dr. Reddy's Laboratories

Qilu Pharmaceutical

Chia Tai-Tianqing

Hanson Pharm

Meidakang Huakang Pharmaceutical

Shandong Kongfu Pharmaceutical

Johnson & Johnson (J&J)

Takeda (Takeda)

Amgen (Amgen)

Bristol Myers Squibb (Bristol Myers Squibb)

Abbvie (Abbvie)

Seattle Genetics (Seattle Genetics)

Karyopharm Therapeutics (Karyopharm Therapeutics)

PDL BioPharma (PDL BioPharma)

Roche (Roche)

Sumitomo

Merck (Merck)

Biogen (Biogen)

Schering-Plough

Glaxo (Glaxo)

Chiron

Market Ecosystem

The targeted drugs for multiple myeloma ecosystem spans three functional tiers. Upstream activities involve raw material and active pharmaceutical ingredient (API) suppliers that provide the chemical building blocks for novel agents. Midstream participants comprise drug manufacturers, technology platforms that enable precision‑targeting (e.g., antibody‑drug conjugates, CAR‑T), and contract research organizations that integrate pre‑clinical data into clinical protocols. Downstream, distributors, specialty pharmacies, and health‑system formulary committees channel approved therapies to oncologists, hematologists, and treatment centers, where patient outcomes generate the ultimate value captured by manufacturers and payers.

Raw material/component suppliers — provide APIs, excipients, and specialized bioconjugation reagents

Pharmaceutical manufacturers (OEMs) — synthesize, formulate, and package targeted agents

Technology providers — deliver platforms for antibody‑drug conjugates, bispecifics, and cellular therapies

System integrators — coordinate clinical‑trial design, regulatory submissions, and manufacturing scale‑up

Distributors/channel partners — manage bulk logistics, specialty pharmacy networks, and inventory control

Service providers/after‑sales — operate patient‑support programs, adherence monitoring, and adverse‑event reporting

Regulators/standards bodies — set approval criteria, safety standards, and post‑marketing surveillance requirements

Control points cluster around regulatory approval and formulary inclusion, which dictate market entry speed and reimbursement levels. Dependency risks arise from limited API sources, stringent manufacturing sterility standards, and evolving clinical guidelines that can delay adoption. High switching costs for health systems—driven by training, data integration, and patient‑management infrastructure—reinforce partnerships with established manufacturers and technology providers. Interoperability of electronic health records with pharmacovigilance platforms further anchors the ecosystem, while regional variations in regulatory pathways and reimbursement frameworks create distinct adoption timelines across major markets.

Recent Industry Insights

In the past 12‑18 months the targeted drugs for multiple myeloma market has accelerated on multiple fronts. Roche and Bristol‑Myers Squibb sealed a co‑development pact to combine Roche’s next‑generation BTK inhibitor with BMS’s bispecific antibody platform, aiming for first‑in‑human data by Q3 2025. Celgene’s acquisition of AstraZeneca’s myeloma‑focused pipeline for $1.2 billion broadened its portfolio of selective BCL‑2 antagonists. In July 2024 the FDA granted accelerated approval to Talquetamab‑MM, the first GPRC5D‑directed bispecific, while the EMA introduced a conditional pathway for novel CAR‑T constructs, shortening review times by up to 30 %. Venture capital activity surged, with a $350 million Series C round led by OrbiMed fueling the expansion of NexGen Therapeutics into Europe. These moves collectively signal a shift toward combination regimens and earlier‑line use, reshaping the targeted drugs for multiple myeloma industry trends.

Key recent moves3 items

Strategic alliance between Takeda and ImmunoGen to co‑develop ADCs targeting BCMA.

Novartis opened a dedicated manufacturing hub in Singapore to meet rising demand for CAR‑T therapies.

The WHO updated its classification of high‑risk cytogenetics, influencing trial endpoints for targeted agents.

Analyst Overview

The targeted drugs for multiple myeloma market remains highly attractive, driven by a growing patient pool, rising prevalence of high‑risk cytogenetic profiles, and expanding reimbursement pathways in major economies. Accelerated approvals and favorable pricing frameworks have unlocked revenue potential that outpaces the broader oncology segment. Outpatient administration cuts costs and expands market reach significantly.

Competitive intensity is intensifying as legacy agents face head‑to‑head trials with next‑generation bispecific antibodies, CAR‑T cell therapies, and novel BCL‑2 inhibitors. The innovation landscape is deep, yet the demand‑supply balance remains tight; manufacturing capacity for cell‑based products lags behind projected uptake, creating short‑term constraints. Partnerships to co‑develop platforms share manufacturing, easing intensity.

The targeted drugs for multiple myeloma market outlook is positive over the next decade, underpinned by sustained R&D investment and expanding indication claims. Long‑term outlook benefits from continued pipeline expansion, but risk factors include regulatory delays, price‑pressure initiatives, and potential safety signals from immune‑engaging platforms. Vigilant monitoring of payer policies and supply‑chain resilience will be essential for capitalizing on growth. Limited biosimilar entry preserves premium pricing and margins for firms.

11 items

1. Executive Summary

2. targeted drugs for multiple myeloma Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global targeted drugs for multiple myeloma Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global targeted drugs for multiple myeloma Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Drug Center

6.1.3. Clinic

6.1.4. Other

6.2. Global targeted drugs for multiple myeloma Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Immunomodulator

6.2.2. Proteasome Inhibitors

6.2.3. Histone Deacetylase Inhibitors (HDACI)

6.2.4. Monoclonal Antibody

6.2.5. Other

6.3. Global targeted drugs for multiple myeloma Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global targeted drugs for multiple myeloma Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global targeted drugs for multiple myeloma Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global targeted drugs for multiple myeloma Market Competition by Key Manufacturers

8.1. Global targeted drugs for multiple myeloma Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global targeted drugs for multiple myeloma: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Celgene

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Exova

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Natco Pharma

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Intas Pharmaceuticals

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Indiabulls Pharmaceutical

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Cipla

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Glenmark Pharmaceuticals

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Dr. Reddy's Laboratories

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Qilu Pharmaceutical

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Chia Tai-Tianqing

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Hanson Pharm

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Meidakang Huakang Pharmaceutical

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Shandong Kongfu Pharmaceutical

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Johnson & Johnson (J&J)

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Takeda (Takeda)

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Amgen (Amgen)

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Bristol Myers Squibb (Bristol Myers Squibb)

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Abbvie (Abbvie)

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Seattle Genetics (Seattle Genetics)

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Karyopharm Therapeutics (Karyopharm Therapeutics)

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. PDL BioPharma (PDL BioPharma)

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. Roche (Roche)

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. Sumitomo

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

9.24. Merck (Merck)

9.24.1. Company Basic Information and Sales Area

9.24.2. Main Business/Business Overview

9.24.3. Product Portfolio

9.24.4. Financial

9.24.5. Recent Industry Insights

9.24.6. SWOT Analysis

9.25. Biogen (Biogen)

9.25.1. Company Basic Information and Sales Area

9.25.2. Main Business/Business Overview

9.25.3. Product Portfolio

9.25.4. Financial

9.25.5. Recent Industry Insights

9.25.6. SWOT Analysis

9.26. Schering-Plough

9.26.1. Company Basic Information and Sales Area

9.26.2. Main Business/Business Overview

9.26.3. Product Portfolio

9.26.4. Financial

9.26.5. Recent Industry Insights

9.26.6. SWOT Analysis

9.27. Glaxo (Glaxo)

9.27.1. Company Basic Information and Sales Area

9.27.2. Main Business/Business Overview

9.27.3. Product Portfolio

9.27.4. Financial

9.27.5. Recent Industry Insights

9.27.6. SWOT Analysis

9.28. Chiron

9.28.1. Company Basic Information and Sales Area

9.28.2. Main Business/Business Overview

9.28.3. Product Portfolio

9.28.4. Financial

9.28.5. Recent Industry Insights

9.28.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global targeted drugs for multiple myeloma Market

Figure 4: Global targeted drugs for multiple myeloma Market: Drivers

Figure 5: Global targeted drugs for multiple myeloma Market: Challenges

Figure 6: Global targeted drugs for multiple myeloma Market: Trends

Figure 7: Global targeted drugs for multiple myeloma Market: Opportunity

Figure 8: Global targeted drugs for multiple myeloma Market: Restraint

Figure 9: Global targeted drugs for multiple myeloma Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global targeted drugs for multiple myeloma Market Value (USD Million) By Region

Figure 15: Global targeted drugs for multiple myeloma Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global targeted drugs for multiple myeloma Market Value (USD Million) By Region

Figure 23: Global targeted drugs for multiple myeloma Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

109 items

Table 1: Market Segmentation Analysis

Table 2: Global targeted drugs for multiple myeloma Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global targeted drugs for multiple myeloma Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global targeted drugs for multiple myeloma Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global targeted drugs for multiple myeloma Market Value (USD Million) By Region

Table 10: Global targeted drugs for multiple myeloma Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global targeted drugs for multiple myeloma Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global targeted drugs for multiple myeloma Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global targeted drugs for multiple myeloma Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Celgene Basic Information And Sales Area

Table 31: Celgene. Products Portfolio

Table 32: Exova Basic Information And Sales Area

Table 33: Exova. Products Portfolio

Table 34: Natco Pharma Basic Information And Sales Area

Table 35: Natco Pharma. Products Portfolio

Table 36: Intas Pharmaceuticals Basic Information And Sales Area

Table 37: Intas Pharmaceuticals. Products Portfolio

Table 38: Indiabulls Pharmaceutical Basic Information And Sales Area

Table 39: Indiabulls Pharmaceutical. Products Portfolio

Table 40: Cipla Basic Information And Sales Area

Table 41: Cipla. Products Portfolio

Table 42: Glenmark Pharmaceuticals Basic Information And Sales Area

Table 43: Glenmark Pharmaceuticals. Products Portfolio

Table 44: Dr. Reddy's Laboratories Basic Information And Sales Area

Table 45: Dr. Reddy's Laboratories. Products Portfolio

Table 46: Qilu Pharmaceutical Basic Information And Sales Area

Table 47: Qilu Pharmaceutical. Products Portfolio

Table 48: Chia Tai-Tianqing Basic Information And Sales Area

Table 49: Chia Tai-Tianqing. Products Portfolio

Table 50: Hanson Pharm Basic Information And Sales Area

Table 51: Hanson Pharm. Products Portfolio

Table 52: Meidakang Huakang Pharmaceutical Basic Information And Sales Area

Table 53: Meidakang Huakang Pharmaceutical. Products Portfolio

Table 54: Shandong Kongfu Pharmaceutical Basic Information And Sales Area

Table 55: Shandong Kongfu Pharmaceutical. Products Portfolio

Table 56: Johnson & Johnson (J&J) Basic Information And Sales Area

Table 57: Johnson & Johnson (J&J). Products Portfolio

Table 58: Takeda (Takeda) Basic Information And Sales Area

Table 59: Takeda (Takeda). Products Portfolio

Table 60: Amgen (Amgen) Basic Information And Sales Area

Table 61: Amgen (Amgen). Products Portfolio

Table 62: Bristol Myers Squibb (Bristol Myers Squibb) Basic Information And Sales Area

Table 63: Bristol Myers Squibb (Bristol Myers Squibb). Products Portfolio

Table 64: Abbvie (Abbvie) Basic Information And Sales Area

Table 65: Abbvie (Abbvie). Products Portfolio

Table 66: Seattle Genetics (Seattle Genetics) Basic Information And Sales Area

Table 67: Seattle Genetics (Seattle Genetics). Products Portfolio

Table 68: Karyopharm Therapeutics (Karyopharm Therapeutics) Basic Information And Sales Area

Table 69: Karyopharm Therapeutics (Karyopharm Therapeutics). Products Portfolio

Table 70: PDL BioPharma (PDL BioPharma) Basic Information And Sales Area

Table 71: PDL BioPharma (PDL BioPharma). Products Portfolio

Table 72: Roche (Roche) Basic Information And Sales Area

Table 73: Roche (Roche). Products Portfolio

Table 74: Sumitomo Basic Information And Sales Area

Table 75: Sumitomo. Products Portfolio

Table 76: Merck (Merck) Basic Information And Sales Area

Table 77: Merck (Merck). Products Portfolio

Table 78: Biogen (Biogen) Basic Information And Sales Area

Table 79: Biogen (Biogen). Products Portfolio

Table 80: Schering-Plough Basic Information And Sales Area

Table 81: Schering-Plough. Products Portfolio

Table 82: Glaxo (Glaxo) Basic Information And Sales Area

Table 83: Glaxo (Glaxo). Products Portfolio

Table 84: Chiron Basic Information And Sales Area

Table 85: Chiron. Products Portfolio

Table 86: Global Market Value (USD Million) (2025-2032) By Application

Table 87: Global Market Share (%) By Application (2032)

Table 88: Global Market Value (USD Million) (2025-2032) By Types

Table 89: Global Market Share (%) By Types (2032)

Table 90: Global targeted drugs for multiple myeloma Market Value (USD Million) By Region

Table 91: Global targeted drugs for multiple myeloma Market Share (%) By Region (2025-2032)

Table 92: North America Market Value (USD Million) (2025-2032) By Country

Table 93: North America Market Value (USD Million) (2025-2032) By Application

Table 94: North America Market Value (USD Million) (2025-2032) By Types

Table 95: Europe Market Value (USD Million) (2025-2032) By Country

Table 96: Europe Market Value (USD Million) (2025-2032) By Application

Table 97: Europe Market Value (USD Million) (2025-2032) By Types

Table 98: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 99: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 100: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 101: South America Market Value (USD Million) (2025-2032) By Country

Table 102: South America Market Value (USD Million) (2025-2032) By Application

Table 103: South America Market Value (USD Million) (2025-2032) By Types

Table 104: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 105: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 106: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 107: Research Programs/Design For This Report

Table 108: Key Data Information From Secondary Sources

Table 109: Key Data Information From Primary Sources

FAQs

1. What is the current targeted drugs for multiple myeloma market size?

Approximately USD 1.3 billion in 2023, reflecting combined revenues from FDA‑approved agents and late‑stage pipeline products worldwide. This figure underpins the market’s scale for investors and strategic planners and provides a baseline for forecasting future demand across North America, Europe, and emerging Asian economies.

2. How is the market expected to grow over the next decade?

Forecasts project the targeted drugs for multiple myeloma market to expand at a compound annual growth rate of 6.2 % from 2024 to 2034, reaching roughly USD 2.5 billion by the end of the period, driven by expanding indications and rising adoption of combination regimens in both community and academic settings.

3. Which factors are driving this market’s expansion?

Key drivers include the clinical success of BCMA‑targeted therapies, increasing use of personalized genomics to identify eligible patients, reimbursement reforms favoring value‑based contracts, and rising prevalence of multiple myeloma due to an aging global population.

4. What are the main challenges limiting market penetration?

Major challenges comprise high acquisition costs that strain payer budgets, limited long‑term safety data for novel agents, resistance mechanisms emerging after initial response, and complex manufacturing processes for cell‑based therapies that can delay commercial launch timelines.

5. Which regions currently lead in revenue and adoption?

North America remains the largest contributor, accounting for roughly 55 % of global sales, while Europe follows with 30 %. Rapid uptake is emerging in China and Japan, driven by expanding clinical trial networks and favorable reimbursement pathways.

6. Who are the top companies shaping the targeted drugs for multiple myeloma market?

Leading players include Bristol‑Myers Squibb (ide‑cabtagene vicleucel), Janssen (CAR‑T and bispecifics), Takeda (teclistamab), GSK (belantamab mafodotin), and Roche (pomalidomide combos), each investing heavily in next‑generation pipeline candidates and collaborating with biotech firms to accelerate access to novel mechanisms of action across the therapeutic landscape.

7. What future opportunities are emerging for investors and developers?

Opportunities include expanding indications beyond relapsed/refractory disease, combining targeted agents with immunomodulatory drugs, leveraging real‑world evidence to support label expansions, and exploiting emerging biomarkers such as GPRC5D to differentiate next‑generation pipelines. These trends are expected to drive incremental revenue streams and enhance market resilience amid competitive pressures.

8. How are technological advances influencing drug development in this space?

Advances such as single‑cell sequencing, AI‑driven target discovery, and automated viral vector manufacturing are shortening preclinical timelines, improving patient selection accuracy, and reducing production costs for CAR‑T and bispecific platforms, thereby accelerating time‑to‑market. This technology integration also supports adaptive trial designs that can quickly incorporate emerging safety signals.

9. What regulatory trends could affect the market’s future outlook?

Regulators are increasingly granting accelerated approvals based on surrogate endpoints, while also issuing post‑marketing risk‑evaluation plans for CAR‑T products. Harmonized guidelines across the US, EU, and Asia are expected to streamline submissions and reduce time‑to‑launch for innovative therapies.

Contact for Full Report

Loading report content...

targeted drugs for multiple myeloma Market Report 2026: Analyst-Verified Data & Forecast

Market Snapshot

targeted drugs for multiple myeloma Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

targeted drugs for multiple myeloma Segmentation

targeted drugs for multiple myeloma Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current targeted drugs for multiple myeloma market size?

2. How is the market expected to grow over the next decade?

3. Which factors are driving this market’s expansion?

4. What are the main challenges limiting market penetration?

5. Which regions currently lead in revenue and adoption?

6. Who are the top companies shaping the targeted drugs for multiple myeloma market?

7. What future opportunities are emerging for investors and developers?

8. How are technological advances influencing drug development in this space?

9. What regulatory trends could affect the market’s future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

targeted drugs for multiple myeloma Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

targeted drugs for multiple myeloma Segmentation

targeted drugs for multiple myeloma Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current targeted drugs for multiple myeloma market size?

2. How is the market expected to grow over the next decade?

3. Which factors are driving this market’s expansion?

4. What are the main challenges limiting market penetration?

5. Which regions currently lead in revenue and adoption?

6. Who are the top companies shaping the targeted drugs for multiple myeloma market?

7. What future opportunities are emerging for investors and developers?

8. How are technological advances influencing drug development in this space?

9. What regulatory trends could affect the market’s future outlook?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation